Michitsugu Kamezaki, Tetsuro Kusaba, Kazumi Komaki, Yohei Fushimura, Noriko Watanabe, Kisho Ikeda, Takashi Kitani, Noriyuki Yamashita, Masahiro Uehara, Yuhei Kirita, Yayoi Shiotsu, Ryosuke Sakai, Takuya Fukuda, Masahiro Yamazaki, Michiaki Fukui, Satoaki Matoba, Keiichi Tamagaki
Clinical and experimental studies have shown that sodium glucose co-transporter 2 inhibitors (SGLT2i) contribute to the prevention of diabetic kidney disease progression. In order to clarify its pharmacological effects on the molecular mechanisms underlying the development of diabetic kidney disease, we administered different doses of the SGLT2i, ipragliflozin, to type 2 diabetic mice. A high-dose ipragliflozin treatment for 8 weeks lowered blood glucose levels and reduced urinary albumin excretion. High- and low-dose ipragliflozin both inhibited renal and glomerular hypertrophy, and reduced NADPH oxidase 4 expression and subsequent oxidative stress...
March 5, 2018: Scientific Reports